Earmark - Oral Anthrax/Plaguevaccine

Agency:		Department of Defense--Military
Bureau:		Research, Development, Test, and Evaluation
Account:		Research, development, test, and evaluation, Defense-wide (97-0400)
Certifying Official:		Deputy Comptroller Program/Budget
Contact Information:		http://WWW.DOD.GOV 703-697-5131

Oral Anthrax/Plaguevaccine

1 recipient will receive $2,800,000.

Year Enacted: 2005

Description: Develops new, safe and effective orally administered vaccines against anthrax and plague or any other microbes used as bioweapons. Avant is working through the DynPort Vaccine Company, LLC and DoD Joint Vaccine Acquisition Program.

Beneficiary/Recipient	Amount ($K)	Program	Type	Address
Avant Immunotherapeutics, Inc	$2,800		For-Profit	Needham, MA

Citation

Source: Appropriations Report Language - Conference

Reference: 108-622

Location: Line 33, Page 345

Citation Excerpt: Oral Anthrax/Plaguevaccine

Last Modified: 16-Apr-2007